ApoE

National Institute on AgingUS$20.3mNational Institute of Neurological Disorders and StrokeUS$1.3m

• RNAi-Mediated Combinatorial Modulation of ApoE, Innate Immune Response, and Tau Pathology for a Disease-Modifying Treatment of Alzheimer's Disease (AD)

  National Institute on AgingUniv of Massachusetts Med Sch WorcesterUS$419.9k2026–2031

• Effect of apoE genotype on eNOS regulation and the development of VCID

  National Institute of Neurological Disorders and StrokeRoskamp InstituteUS$599.8k2026–2031

• Biology and Pathobiology of APOE in Aging and Alzheimer's Disease 2.0

  National Institute on AgingMayo Clinic JacksonvilleUS$4.6m2021–2031

• Neurotoxicity of particulate matter and its interaction with APOE in neurodegeneration

  National Institute of Neurological Disorders and StrokeUniversity of California-irvineUS$668.2k2022–2027

• MOTS-C, APOE, and Alzheimer's disease

  National Institute on AgingUniversity of Southern CaliforniaUS$2.5m2024–2029

• Investigating neutrophilic inflammation as an APOE genotype-specific mediator of neuroinflammation and cognitive decline in aging

  National Institute on AgingMc Laughlin Research InstituteUS$639.4k2024–2029

• APOE Genotype Mediated Effects on Alzheimer Disease Risk and Mechanisms

  National Institute on AgingBoston University Medical CampusUS$795.4k2024–2029

• The effects of APOE genotype in homeostatic microglial function in preclinical APOE mouse model

  National Institute on AgingUniversity of Texas Hlth Sci Ctr HoustonUS$93.9k2023–2029

• Acute and Long-Term Impact of SARS-CoV-2 Infection and its Interaction with APOE on Cognitive Function and Neuropathology in Aging and Alzheimer's Disease

  National Institute on AgingUniversity of MinnesotaUS$700.1k2022–2027

• Delineating systemic roles of APOE genotypes on CNS health

  National Institute on AgingIcahn School of Medicine at Mount SinaiUS$2.9m2026–2030